Favorable Response to Infliximab Treatment in a Patient with Active Crohn Disease and Pyoderma Gangrenosum
Favorable Response to Infliximab Treatment in a Patient with Active Crohn Disease and Pyoderma Gangrenosum
复制标题
活动性克罗恩病和坏疽性脓皮病患者对英夫利昔单抗治疗有良好反应
DOI：
--
复制
发表时间：
2002
影响因子：
1.9
通讯作者：
K. Apostolopoulou
中科院分区：
文献类型：
--
作者：
J. Triantafillidis;P. Cheracakis;Maria Sklavaina;K. Apostolopoulou
坏疽性脓皮病是炎症性肠病的肠外表现，需要细致的医学和/或手术治疗。我们描述了一个46岁的病人谁发展了严重的坏疽性脓皮病期间严重爆发的潜在的克罗恩病的回肠末端。患者对英夫利昔单抗（一种抗肿瘤坏死因子- α的嵌合抗体）治疗反应良好。在基线和第2周和第6周以5 mg/kg/BW的剂量静脉注射该药物。第二次输注前腹部体征和症状以及皮肤病变明显改善。患者目前正在接受英夫利昔单抗维持治疗，剂量为5mg /kg/BW，分为3个剂量加载方案，分别在0、2和6周进行，无治疗间隔为10周，直到下一个加载剂量。皮肤损伤仍处于缓解状态。英夫利昔单抗是治疗克罗恩病和坏疽性脓皮病的一种很有前途的治疗方式。
Pyoderma gangrenosum is an extraintestinal manifestation of inflammatory bowel disease requiring meticulous medical and/or surgical treatment. We describe a 46-year-old patient who developed harsh pyoderma gangrenosum during a severe flare-up of the underlying Crohn disease of the terminal ileum. The patient responded favorably to treatment with infliximab--the chimeric antibody against tumor necrosis factor-alpha. The drug was administered intravenously at a dose 5 mg/kg/BW at baseline and weeks 2 and 6. Abdominal signs and symptoms as well as the skin lesions improved markedly before the second infusion. The patient is presently on infliximab maintenance regimen at a dose of 5 mg/kg/BW being administered as a 3 dose loading regimen at 0, 2 and 6 weeks with a treatment-free interval of 10 weeks until the next loading dose. The skin lesions remained in remission. Infliximab is a promising therapeutic modality for patients with Crohn disease and pyoderma gangrenosum.